Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings

Expert Opinion on Investigational Drugs · Published 2026-03-04 · DOI 10.1080/13543784.2026.2636926

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1080/13543784.2026.2636926

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Advancements in longevity pharmacology research – are we finally seeing clinical progression? · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · Expert Opinion on Investigational Drugs · 2025 · Same journal
• The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Menin inhibitors for adult acute myeloid leukemia: 2025 update · Expert Opinion on Investigational Drugs · 2025 · Same journal
• Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · Expert Opinion on Investigational Drugs · 2026 · Same journal
• Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · Expert Opinion on Investigational Drugs · 2026 · Same journal
• A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug · Expert Opinion on Investigational Drugs · 2026 · Same journal